BC研究人员获得4900万美元用于基因组学项目-动脉网

BC researchers receive $49M for genomics projects

MobiHealthNews 等信源发布 2025-04-03 17:56



可切换为仅中文







Photo:

照片：

Sebastian Condrea

塞巴斯蒂安·孔德拉

/Getty Images

/盖蒂图片社

Genome British Columbia

基因组不列颠哥伦比亚

(Genome BC), a not-for-profit genomics research company, has secured $49 million in funding for five projects that will be conducted in British Columbia and will utilize genomics to advance personalized healthcare.

不列颠哥伦比亚省的一家非盈利基因组学研究公司（Genome BC）已经获得了4900万加元的资助，用于在该省开展五个项目，这些项目将利用基因组学推动个性化医疗的发展。

According to Genome BC,

根据基因组BC，

the projects are part of research funding announced in March by Genome Canada under the Canadian Precision Health Initiative (CPHI).

这些项目是加拿大基因组公司三月份宣布的加拿大精准健康计划（CPHI）研究资助的一部分。

The initiative makes use of genome sequencing data for more personalized, preventative and cost-effective healthcare.

该计划利用基因组测序数据，以实现更个性化、预防性且更具成本效益的医疗保健。

BC researchers, along with local scientists, will head t

BC研究人员将与当地科学家一起前往

hree of the projects.

三个项目。

In a statement, Genome BC said it contributed $14 million, with an additional $35 million secured from Genome Canada and other co-funding partners, multiplying the impact of Genome BC's investment, with every $1 contributed bringing $2.5 in additional funding.

Genome BC 在一份声明中表示，它贡献了 1400 万加元，并从 Genome Canada 和其他共同资助合作伙伴那里获得了额外的 3500 万加元，使 Genome BC 的投资影响倍增，每贡献 1 加元就能带来 2.5 加元的额外资金。

Additionally,

此外，

Genome BC worked closely with researchers to develop funding applications for the projects aimed at improving hereditary cancer care, boosting drug safety for children and providing early diagnosis of cardiovascular disease, especially in indigenous and underserved communities.

Genome BC与研究人员密切合作，为旨在改善遗传性癌症护理、提高儿童药物安全性以及提供心血管疾病早期诊断（尤其是在土著和服务不足的社区）的项目开发资金申请。

The five projects are:

五个项目是：

Enhancing

增强

population hereditary cancer care through genome sequencing, which takes a look at the under-identification of patients with hereditary cancer risk;

通过基因组测序进行人群遗传性癌症护理，关注遗传性癌症风险患者的识别不足问题；

Expanding pediatric drug safety research;

扩大儿科药物安全研究；

MOSAIC: Genomics and AI for heart health, an initiative that utilizes genomics, AI and imaging to alter and accelerate cardiovascular diagnosis and treatment;

MOSAIC：基因组学与人工智能在心脏健康领域的应用，一项利用基因组学、人工智能和成像技术来改变并加速心血管疾病诊断和治疗的倡议；

Pan-GEM: Genomics and mental health research focused on identifying genetic and environmental risk factors for children and youth with mental health disorders; and

Pan-GEM：基因组学与心理健康研究，专注于识别有心理健康障碍的儿童和青少年的遗传和环境风险因素；以及

PrairieGen, which aims to strengthen genomic research in the prairies by identifying critical biomarkers, genetic variants and risk factors exclusive to Manitoba and Saskatchewan populations.

PrairieGen旨在通过识别曼尼托巴省和萨斯喀彻温省人群独有的关键生物标志物、基因变异和风险因素，加强草原地区的基因组研究。

'This important investment in genomics driven healthcare innovation positions British Columbia at the forefront of precision health,' Federica Di Palma, chief scientific officer and vice president, research and innovation at Genome BC, said in a statement.

“这项针对基因组学驱动的医疗保健创新的重要投资，使不列颠哥伦比亚省走到了精准健康领域的前沿，”不列颠哥伦比亚基因组计划（Genome BC）的首席科学官兼研究与创新副总裁费德里卡·迪·帕尔马在一份声明中表示。

'These projects not only advance cutting-edge science but also directly aim to provide solutions to pressing healthcare challenges which will benefit patients and contribute to a more resilient, equitable and innovation-driven health system for BC and Canada.'

“这些项目不仅推动了前沿科学的发展，还直接旨在为紧迫的医疗挑战提供解决方案，这将使患者受益，并为不列颠哥伦比亚省和加拿大建设一个更具韧性、更加公平、创新驱动的医疗系统做出贡献。”

THE LARGER TREND

更大的趋势

In February,

二月，

Genome BC funded a set of research projects aimed at addressing the risk associated with a strain of avian influenza, of the H5N1 subtype.

基因组BC资助了一系列研究项目，旨在解决与H5N1亚型禽流感病毒株相关的风险。

The BC Centre for Disease Control (BCCDC) conducted the projects in partnership with the Provincial Health Officer, the Ministry of Health, the Ministry of Agriculture and Food, and researchers from the University of British Columbia.

不列颠哥伦比亚疾病控制中心（BCCDC）与省卫生官员、卫生部、农业和食品部以及不列颠哥伦比亚大学的研究人员合作开展了这些项目。

BCCDC and the BC Ministry of Agriculture and Food are investigating how air currents could contribute to the virus' spread, develop antibody tests to detect the level of exposure in human populations, implement wastewater surveillance as an early warning system and increase genomic analysis methods to understand how the virus might be changing. .

不列颠哥伦比亚省疾病控制中心（BCCDC）和不列颠哥伦比亚省农业和食品部正在调查气流如何促进病毒传播，开发抗体测试以检测人群中的暴露水平，实施废水监测作为早期预警系统，并加强基因组分析方法以了解病毒可能如何变化。

Other companies involved in genome sequencing include

参与基因组测序的其他公司包括

Sano Genetics

赛诺遗传学

, which provides free home genome sequencing and data reports that customers can choose to include in health research.

，该公司提供免费的家庭基因组测序和数据报告，客户可以选择将其包含在健康研究中。

In 2024,

2024年，

Sano supported Neuron23 in the NEULARK Phase 2 clinical trial exploring NEU-411, a brain-penetrant LRRK2 inhibitor with the potential to slow disease progression in Parkinson’s disease.

Sano 支持 Neuron23 进行 NEULARK 二期临床试验，研究 NEU-411，一种可穿透大脑的 LRRK2 抑制剂，具有减缓帕金森病进展的潜力。

Sano Genetics is providing saliva test kits to identify individuals with LRRK2-driven Parkinson’s disease, offering genetic counseling and facilitating trial referrals to streamline the patient journey.

Sano Genetics正在提供唾液测试套件，以识别由LRRK2驱动的帕金森病患者，同时提供遗传咨询并协助试验转诊，以简化患者的治疗过程。

Last year, Sano raised $11.4 million in funding, two years after securing $11 million in a Series A funding round.

去年，Sano公司在获得1100万美元的A轮融资两年后，又筹集了1140万美元的资金。

In 2021, the company scored

2021年，该公司得分

$3.2 million (£2.5 million) in a seed funding round

320万美元（250万英镑）的种子轮融资

led by Episode1 Ventures. Seedcamp, Cambridge Enterprise,

由Episode1 Ventures领投，Seedcamp、Cambridge Enterprise参与。

January Ventures

一月创投

and a handful of unnamed angel investors also participated.